Molecular Diagnostics, NGS and Genetic Testing Billing in 2027: A Revenue Cycle Guide for Laboratories

Molecular diagnostics continues to change what is possible in medicine.

Genetic testing, next generation sequencing, biomarker testing and other advanced diagnostics are giving clinicians increasingly sophisticated information to help diagnose disease, guide treatment and support precision medicine.

For laboratories, these advances create significant opportunities.

They also create an important financial question.

Can your revenue cycle keep up with your test menu?

Molecular diagnostics billing, NGS billing and genetic testing billing can involve considerably more than submitting a claim after testing is complete.

Eligibility, prior authorization, medical necessity, documentation, coding, payer requirements, claim edits, denials and reimbursement all may affect the financial outcome of a test.

For laboratories investing significant resources into sophisticated testing, the revenue cycle needs to be capable of supporting that sophistication.

That means laboratory billing increasingly begins before the claim.

Why Is Molecular Diagnostics Billing So Complex?

Molecular diagnostics billing can become complex because reimbursement depends on more than the test performed.

The patient's health plan matters. The payer matters. Coverage policies matter. Documentation matters. Medical necessity matters. Coding matters. Prior authorization may matter. The information submitted with the claim matters. The timing of each step can matter.

That means two seemingly similar tests can encounter very different reimbursement pathways depending on the patient and payer.

A strong molecular diagnostics revenue cycle should therefore provide visibility before, during and after claim submission, supported by laboratory billing software and RCM built around that complexity.

The objective is not simply to submit claims faster. The objective is to submit cleaner claims while identifying potential reimbursement problems earlier.

Is Your Revenue Cycle Keeping Up With Your Test Menu?

As molecular testing becomes more sophisticated, your billing operation needs to keep pace. ADS supports molecular and genetics laboratory billing with technology and revenue cycle services designed around complex laboratory reimbursement.

Explore Molecular and Genetics Billing Solutions  |  Explore All ADS Laboratory Billing and RCM Solutions

Why NGS Billing Requires a Different Revenue Cycle Mindset

Next generation sequencing can produce sophisticated clinical information. The billing workflow surrounding NGS can be sophisticated as well.

A laboratory may need to understand coverage criteria, patient eligibility, payer requirements, documentation, coding and authorization requirements before reimbursement can occur.

Waiting until testing is completed to begin thinking about reimbursement can leave the billing team solving problems that might have been identified earlier.

A stronger NGS billing strategy moves appropriate financial checks upstream.

That may include verifying patient and insurance information, checking eligibility, identifying possible authorization requirements and making sure necessary information reaches the revenue cycle.

The objective is not to allow billing requirements to interfere with appropriate clinical care. It is to give the laboratory greater financial visibility around the testing it performs.

Prior Authorization Needs to Be Part of the Conversation Earlier

Prior authorization can create significant administrative challenges for laboratories performing complex testing.

Timing is one of the most important issues.

Discovering an authorization requirement after testing has been performed can leave the laboratory with fewer options than identifying the requirement earlier.

This makes prior authorization more than a billing department responsibility.

It can require coordination among laboratory operations, ordering providers, revenue cycle staff and technology.

Laboratories should establish workflows that help identify potential authorization requirements as early as practical.

Billing technology should support that process by helping the team recognize accounts requiring attention rather than relying entirely on manual research.

How Much Revenue Is Being Delayed Before the Claim Is Even Submitted?

Eligibility and authorization issues can create downstream billing work. ADS can help your laboratory review front end revenue cycle workflows and identify opportunities to improve visibility before claims reach the payer.

Talk With an ADS Laboratory RCM Specialist

Genetic Testing Billing Starts Before Claim Submission

The financial workflow for genetic testing should begin well before someone presses the submit button.

Accurate patient information matters. Accurate insurance information matters. Eligibility may need to be confirmed. Potential payer requirements may need to be identified. Documentation needs to support the testing performed. Coding needs to accurately represent the service.

Only then does claim submission become the central issue.

This is why laboratory revenue cycle management should be viewed as an operational process rather than simply a billing department function.

The more complex the testing becomes, the more important that distinction becomes.

Denial Management Should Produce More Than Reworked Claims

A molecular testing claim is denied. Someone identifies the denial. Someone researches it. Someone determines what happened. Additional information may be required. The claim may need to be corrected, resubmitted or appealed. Then the laboratory waits again.

Even when the claim is eventually paid, the laboratory has consumed additional administrative resources and extended the time between testing and payment.

Multiply that process across hundreds of claims and denial management becomes a significant operational issue.

This is why laboratories should look beyond denial rework.

Denial information should become prevention intelligence.

If the same authorization, eligibility, documentation or payer issue repeatedly generates denials, the laboratory should be able to recognize that pattern and determine whether the problem can be addressed earlier.

The best denial strategy is not simply becoming faster at fixing denied claims. It is reducing preventable denials.

For a closer look at one of the more demanding categories of denials in this space, see avoiding denials on high complexity molecular and genetic panels.

Stop Treating Every Denial Like a New Problem

Your denial data may already be telling you where your revenue cycle needs attention. ADS laboratory billing technology and ADSRCM help laboratories track claims, manage denials and gain greater visibility into revenue cycle performance.

Explore ADS Laboratory Billing Software

Your LIS and Billing Platform Should Not Operate in Separate Worlds

Molecular and genetic laboratories generate significant amounts of information.

The revenue cycle depends on some of that information moving efficiently from laboratory operations into billing workflows.

When systems remain disconnected, people often become the integration layer.

Staff members reenter information. They research missing data. They reconcile records. They move between systems. They create spreadsheets to fill information gaps.

Every additional manual step consumes time and can introduce errors.

LIS and LIMS billing integration can create a more consistent flow of information between laboratory operations and financial workflows.

ADS and ADSRCM support integration with virtually any LIS or LIMS, as well as integrations with other systems when needed.

The goal is straightforward. Laboratory information should flow into the revenue cycle without creating unnecessary administrative work.

Have an LIS or LIMS Integration Question?

Talk with ADS about your current laboratory technology environment and how billing can fit into it.

Discuss Your LIS or LIMS Integration

PAMA and the 2027 Clinical Laboratory Fee Schedule

Molecular and genetic laboratories should also be watching Medicare reimbursement as 2027 approaches.

The 2026 PAMA data reporting period ended July 31, 2026.

CMS states that the reporting period used applicable information collected from January 1 through June 30, 2025.

The reported information will be used as part of the Clinical Laboratory Fee Schedule process for 2027 through 2029.

There is no PAMA phase in reduction for 2026.

Beginning January 1, 2027, payment reductions resulting from implementation of private payer rate data may not exceed 15 percent per year compared with the payment amount established for a test in the preceding year through 2029.

That does not mean every test will experience a 15 percent reduction. The 15 percent figure is the statutory annual reduction cap.

For laboratory executives, this makes test level and payer level financial visibility particularly important.

Laboratories should understand what they are collecting, how reimbursement differs among payers, where denials originate and how quickly earned revenue becomes cash. For the broader Q4 picture across the full test menu, see laboratory billing and RCM trends for 2027.

What Should Molecular Laboratories Measure?

Laboratory executives should be able to answer practical financial questions without waiting weeks for manually assembled reports.

What are we collecting by test? What are we collecting by payer? Which tests generate the most denials? Which payers create the most denials? How much A/R is older than 90 days? Where do eligibility problems originate? Where do authorization problems originate? How long does reimbursement take? How much manual intervention does a typical claim require? Which denial reasons repeat most often?

Those answers transform billing data into operational intelligence.

A laboratory revenue cycle should tell leadership more than how much money was collected last month. It should help explain why.

Should a Molecular Laboratory Keep Billing In House or Outsource RCM?

There is no universal answer.

A molecular laboratory with an experienced internal billing team may benefit from stronger laboratory billing software, automation, analytics and integration.

Another laboratory may find that recruiting, training and retaining specialized billing personnel consumes too many internal resources.

That laboratory may benefit from outsourced laboratory revenue cycle management.

Other laboratories may need a combination of technology and outside expertise.

ADS supports both approaches.

Laboratories can use ADS technology with their internal teams or work with ADSRCM for outsourced revenue cycle management.

The conversation can therefore begin with the laboratory's operational needs rather than a predetermined billing model.

Which Laboratory Billing Model Makes Sense for You?

In house billing and outsourced laboratory RCM each have advantages. ADS supports both, which means we can begin by looking at your laboratory rather than trying to fit your operation into one model.

Discuss Your Laboratory Billing Options  |  Compare ADS Laboratory Billing Software and RCM Options

AMP 2026 Highlights Where Molecular Medicine Is Going

The Association for Molecular Pathology Annual Meeting & Expo takes place in Seattle this November.

The program provides a useful look at the direction of molecular medicine.

Topics include biomarker testing stewardship, NGS bioinformatics, advanced molecular and cytogenomic methodologies, genetic testing reference materials and precision care.

These scientific conversations reinforce something laboratory executives already know.

Testing is not becoming simpler. It is becoming more sophisticated.

Revenue cycle operations need to evolve alongside that sophistication.

Meet ADS at AMP 2026

November 10 through 14, 2026

Seattle

ADS Booth #1901

If you are attending AMP, bring us your toughest revenue cycle question.

Molecular diagnostics billing. NGS reimbursement. Genetic testing billing. Prior authorization. Eligibility. Denials. A/R. LIS integration. Staffing. Or simply whether your existing billing operation could be performing better.

Schedule Time With ADS at AMP  |  Explore ADS Molecular Billing Solutions

Frequently Asked Questions About Molecular Diagnostics and NGS Billing

What is molecular diagnostics billing?

Molecular diagnostics billing is the revenue cycle process associated with molecular testing. It can include patient and payer information, eligibility, authorization, documentation, coding, claim submission, payment posting, denial management and accounts receivable follow up.

What is NGS billing?

NGS billing refers to revenue cycle processes associated with next generation sequencing. Depending on the test and payer, the workflow may involve coverage requirements, coding, documentation, medical necessity, prior authorization and other payer specific requirements.

Why can genetic testing billing be complicated?

Genetic testing billing may involve different coverage policies, authorization requirements, documentation requirements, coding considerations and payer rules. These requirements can vary by patient plan and test.

Does genetic testing require prior authorization?

Some genetic tests and payer plans may require prior authorization while others may not. Laboratories need workflows that help identify applicable payer requirements as early as practical.

How can molecular laboratories reduce billing denials?

Laboratories can analyze denial patterns and examine upstream processes involving patient information, eligibility, authorization, documentation, coding and payer requirements. Repeated denial causes can help identify areas where workflow changes may prevent future problems.

Can molecular laboratory billing software integrate with an LIS or LIMS?

Yes. Integration can help necessary information move more efficiently between laboratory operations and billing. ADS and ADSRCM support integration with virtually any LIS or LIMS.

Should a molecular laboratory outsource billing?

The answer depends on staffing, expertise, technology, payer mix, test mix and financial objectives. Some laboratories benefit from maintaining billing internally with stronger technology while others may benefit from outsourced laboratory RCM. ADS supports both models.

Better Science Deserves a Revenue Cycle That Can Keep Up

Molecular diagnostics will continue advancing. NGS will continue evolving. Genetic testing will continue creating new possibilities for clinicians and patients.

Laboratory revenue cycle operations need to evolve with them.

ADS and ADSRCM support molecular, genetics, NGS, clinical, pathology, toxicology and specialty laboratories with billing software, automation, analytics, integrations and specialized revenue cycle services.

Request a Laboratory Revenue Assessment  |  Schedule a Personalized Laboratory Billing Demo

Explore ADS Laboratory Billing Software and RCM  |  Explore Molecular and Genetics Laboratory Billing